Trending Alert: These 5 Companies Are Trending Now

Tickers Inside Powered by [FinancialMarketMovers.com]( Good Morning! Below is a list of 5 stocks that are trending with positive investor sentiment, news headlines, and buy ratings from top Wall Street analysts. Our editors are keeping an eye on these stocks and adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [The New Epicenter for Lithium!]( company makes big acquisition in new epicenter of Lithium supply for EV's! [Get Symbol]( --------------------------------------------------------------- [SLM, SLM]( Summary: SLM Corporation (Sallie Mae) is a bellwether in education finance in the United States, with market presence for more than 40 years. The company is the nation's saving, planning, and paying for college company. Whether college is a long way off or just around the corner, Sallie Mae offers products that promote responsible personal finance, including private education loans, Upromise rewards, scholarship search, college financial planning tools, and online retail banking. It also offers a range of deposit products insured by the Federal Deposit Insurance Corporation ('FDIC'). The company's Private Education Loans portfolio consists of education loans to students or their families, which are not made, insured or guaranteed by any state or federal government. The company also undertakes additional funding, liquidity and revenues through the sale or securitization of loan assets, which it originates as well as the servicing of the loan assets that are sold to third parties. Richard Shane analyst at J.P. Morgan reiterated coverage on [SLM (SLM)](in the Financial sector with a Buy rating and has set a price target of $18. Our data shows [SLM]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $19.40. In addition, TradingView issued a Strong Buy rating for [SLM]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on SLM, please click here >>]( [Vertex Pharmaceuticals, VRTX]( Summary: Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA. Salveen Richter analyst at Goldman Sachs reiterated coverage on [Vertex Pharmaceuticals (VRTX)](in the Healthcare sector with a Buy rating and has set a price target of $442. Our data shows [Vertex Pharmaceuticals]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $430.67. In addition, TradingView issued a Strong Buy rating for [VRTX]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on VRTX, please click here >>]( --------------------------------------------------------------- Sponsor [New EV Lithium Player?]( company surges over 178% after recent acquisition in new Lithium epicenter! [See Report]( --------------------------------------------------------------- [Incyte, INCY]( Summary: Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of ster1535-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older. Andrew Berens analyst at Leerink Partners reiterated coverage on [Incyte (INCY)](in the Healthcare sector with a Buy rating and has set a price target of $78. Our data shows [Incyte]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $78.80. In addition, TradingView issued a Strong Buy rating for [INCY]( over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on INCY, please click here >>]( [L3Harris Technologies, LHX]( Summary: L3Harris Technologies is an agile global aerospace and defense technology innovator, delivering end-to-end solutions that meet customers' mission-critical needs. The company provides advanced defense and commercial technologies across space, air, land, sea and cyber domains. Kenneth Herbert analyst at RBC Capital reiterated coverage on [L3Harris Technologies (LHX)](in the Industrials sector with a Buy rating and has set a price target of $225. Our data shows [L3Harris Technologies]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $232.80. In addition, TradingView issued a Strong Buy rating for [LHX]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on LHX, please click here >>]( --------------------------------------------------------------- Sponsor [AI "wealth window" will close January 9, 2024?]( Next-generation AI technology will create the first $100 TRILLION industry. AI 2.0 will open a brief “wealth window”… That will slam shut January 9, 2024. [>>HERE is everything you need now]( --------------------------------------------------------------- [Integra Lifesciences, IART]( Summary: Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Orthopedics and Tissue Technologies (OTT). The CSS business offers global, market-leading technologies, brands and instrumentation. The global commercial network includes clinical specialists, a large direct global sales force and strategic partnerships and distributors that serve hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers and health care providers in North America, South America, Europe, Asia Pacific, Middle East and Africa. The Tissue Technologies segment includes wound reconstruction and repair products, bone grafts and nerve and tendon repair products. Richard Newitter analyst at Truist Financial reiterated coverage on [Integra Lifesciences (IART)](in the Healthcare sector with a Hold rating and has set a price target of $44. Our data shows [Integra Lifesciences]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target of $47.00. In addition, TradingView issued a Buy rating for [IART]( over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on IART, please click here >>]( --------------------------------------------------------------- Sponsor [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [FinancialMarketMovers.com]( --------------------------------------------------------------- Sponsor [Tiny Lithium Stock Surge!]( t miss out on this tiny stock poised to surge in a massive $183B market opportunity! [Get the Free Report]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( FinancialMarketMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( This is part of your free subscription to FinancialMarketMovers. FinancialMarketMovers.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123